Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 3;21(1):242.
doi: 10.1186/s12967-023-03958-2.

Natural killer cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a multi-site clinical assessment of ME/CFS (MCAM) sub-study

Troy D Querec  1 , Jin-Mann S Lin  2 , Yang Chen  2 , Britany Helton  2 , Andreas M Kogelnik  3 , Nancy G Klimas  4 , Daniel L Peterson  5 , Lucinda Bateman  6 , Charles Lapp  7 , Richard N Podell  8 , Benjamin H Natelson  9 , Elizabeth R Unger  2 ; MCAM Study Group
Collaborators, Affiliations

Natural killer cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a multi-site clinical assessment of ME/CFS (MCAM) sub-study

Troy D Querec et al. J Transl Med. .

Abstract

Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a multisystem illness characterized by substantial reduction in function accompanied by profound unexplained fatigue not significantly relieved by rest, post-exertional malaise, and other symptoms. Reduced natural killer (NK) cell count and cytotoxicity has been investigated as a biomarker for ME/CFS, but few clinical laboratories offer the test and multi-site verification studies have not been conducted.

Methods: We determined NK cell counts and cytotoxicity in 174 (65%) ME/CFS, 86 (32%) healthy control (HC) and 10 (3.7%) participants with other fatigue associated conditions (ill control [IC]) from the Multi-Site Clinical Assessment of ME/CFS (MCAM) study using an assay validated for samples shipped overnight instead of testing on day of venipuncture.

Results: We found a large variation in percent cytotoxicity [mean and (IQR) for ME/CFS and HC respectively, 34.1% (IQR 22.4-44.3%) and 33.6% (IQR 22.9-43.7%)] and no statistically significant differences between patients with ME/CFS and HC (p-value = 0.79). Analysis stratified on illness domain measured with standardized questionnaires did not identify an association of NK cytotoxicity with domain scores. Among all participants, NK cytotoxicity was not associated with survey results of physical and mental well-being, or health factors such as history of infection, obesity, smoking, and co-morbid conditions.

Conclusion: These results indicate this assay is not ready for clinical implementation and studies are needed to further explore immune parameters that may be involved in the pathophysiology of ME/CFS.

Keywords: Comorbidity; Cytotoxicity; Multicenter study; Multimorbidity (multiple medical conditions); Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS); Natural killer cell (NK).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a competing interest.

Figures

Fig. 1
Fig. 1
Participant Enrolment by Healthy Control (HC), Ill Control (IC), and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Exclusions from Analysis
Fig. 2
Fig. 2
Box and whisker plots of Natural Killer (NK) Cell Cytotoxicity and Concentration by Illness Group A NK cytotoxicity B NK cell concentration in blood. The top and bottom of the boxes are the 25% and 75% quartiles of NK cytotoxicity. The horizontal lines within the box are the medians, and the diamonds are the means. The points are individual participant results
See this image and copyright information in PMC

References

    1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. Ann Intern Med. 1994;121(12):953–959. doi: 10.7326/0003-4819-121-12-199412150-00009. - DOI - PubMed
    1. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270(4):327–338. doi: 10.1111/j.1365-2796.2011.02428.x. - DOI - PMC - PubMed
    1. Jason LA, Evans M, Porter N, Brown M, Brown A, Hunnell J, et al. The development of a revised Canadian myalgic encephalomyelitis chronic fatigue syndrome case definition. Am J Biochem Biotechnol. 2010;6(2):120–135. doi: 10.3844/ajbbsp.2010.120.135. - DOI
    1. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. In: Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. Washington: National Academies Press; p. 148–50. 2015. https://www.ncbi.nlm.nih.gov/books/NBK284894/. Accessed 14 Nov 2022.
    1. Cortes Rivera M, Mastronardi C, Silva-Aldana C, Arcos-Burgos M, Lidbury B. Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review. Diagnostics. 2019;9(3):91. doi: 10.3390/diagnostics9030091. - DOI - PMC - PubMed